Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults

医学 脂肪变性 内科学 糖尿病前期 代谢综合征 脂肪性肝炎 瞬态弹性成像 胃肠病学 肝硬化 脂肪肝 糖尿病 2型糖尿病 人口 肝病 超重 非酒精性脂肪肝 慢性肝病 疾病 丙氨酸转氨酶 体质指数 内分泌学 血脂异常 肥胖 丙氨酸转氨酶 胰岛素抵抗 肝炎 空腹血糖受损 肝活检 脂蛋白
作者
Herbert Tilg,Salvatore Petta,Norbert Stefan,Giovanni Targher
出处
期刊:JAMA [American Medical Association]
标识
DOI:10.1001/jama.2025.19615
摘要

Importance Metabolic dysfunction–associated steatotic liver disease (MASLD) includes a range of liver conditions, progressing from isolated steatosis (characterized by fat accumulation in the liver without inflammation) to metabolic dysfunction–associated steatohepatitis (MASH), which involves fat accumulation and inflammation in the liver. The presence of MASLD is associated with increased morbidity and mortality due to liver-related complications, hepatocellular carcinoma, cardiovascular disease, and certain extrahepatic cancers. Observations The most common chronic liver disease worldwide, MASLD affects approximately 30% to 40% of the general adult population globally (with varying prevalence across continents), including approximately 60% to 70% of individuals with type 2 diabetes and approximately 70% to 80% of those with obesity. It is typically diagnosed based on an ultrasonographic finding of hepatic steatosis, along with at least 1 of 5 features of the metabolic syndrome (abdominal overweight or obesity, prediabetes or type 2 diabetes, hypertension, elevated level of plasma triglycerides, and low level of high-density lipoprotein cholesterol) for women who consume less than 140 g/wk of alcohol (<2 standard drinks/d) and for men who consume less than 210 g/wk (<3 standard drinks/d) and have no other known causes of steatosis such as use of a particular medication (eg, corticosteroids, tamoxifen, or methotrexate), hepatitis C, or iron overload. Other risk factors for MASLD include older age (≥50 years) and male sex (male:female ratio approximately 2). The Fibrosis-4 index (a scoring system incorporating age, serum levels of aspartate aminotransferase and alanine aminotransferase, and platelet count) and vibration-controlled transient elastography (a noninvasive imaging technique) are commonly used to stage hepatic fibrosis in patients with MASLD. Cardiovascular disease is the leading cause of death, followed by certain extrahepatic cancers (primarily gastrointestinal, breast, and gynecologic cancer) and liver-related complications, including cirrhosis, hepatic decompensation (ascites, hepatic encephalopathy, or variceal bleeding), and hepatocellular carcinoma. First-line treatment of MASLD involves behavioral modifications (including hypocaloric low-carbohydrate and low-fat diets, physical exercise, and avoidance of alcohol) and management of type 2 diabetes, obesity, hypertension, and hyperlipidemia. Bariatric surgery should be considered for patients with MASLD and a body mass index greater than 35. Resmetirom (a liver-directed, thyroid hormone receptor β-selective agonist) and subcutaneous semaglutide (a glucagon-like peptide-1 receptor agonist) are conditionally approved by the US Food and Drug Administration (FDA) for the treatment of adults with MASH who have moderate to advanced fibrosis. Conclusions A highly prevalent condition among adults worldwide, MASLD is associated with liver-related complications, hepatocellular carcinoma, cardiovascular disease, and certain extrahepatic cancers. First-line treatment includes behavioral modifications, including a weight-reducing diet, physical exercise, and avoidance of alcohol. Resmetirom and semaglutide are conditionally FDA-approved medications for the treatment of adults with MASH and moderate to advanced fibrosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
情怀的应助被天天学习采纳,获得10
1秒前
唐唐今今完成签到 ,获得积分10
3秒前
小二郎的应助被风吹麦浪采纳,获得10
3秒前
yanchen发布了新的文献求助10
3秒前
3秒前
3秒前
CipherSage的应助被luan采纳,获得10
3秒前
牛哞发布了新的文献求助10
5秒前
朱朱发布了新的文献求助10
6秒前
sin完成签到 ,获得积分10
6秒前
斑马兽完成签到,获得积分10
7秒前
乐乐的应助被gaoyi12356采纳,获得10
7秒前
YXH给YXH的求助进行了留言
8秒前
9秒前
9秒前
liu45kf完成签到,获得积分10
9秒前
kongqing完成签到,获得积分10
9秒前
拼搏的大地完成签到,获得积分10
9秒前
mzn6664发布了新的文献求助10
10秒前
黄毛虎发布了新的文献求助10
10秒前
11秒前
阿北洛完成签到,获得积分10
13秒前
13秒前
Jasper的应助被gaoyi12356采纳,获得10
14秒前
ian发布了新的文献求助10
14秒前
彤航完成签到,获得积分10
15秒前
15秒前
吱吱发布了新的文献求助10
15秒前
Qin完成签到,获得积分0
15秒前
15秒前
七七发布了新的文献求助10
17秒前
所所的应助被鸡翅爱睡觉采纳,获得10
17秒前
luan发布了新的文献求助10
18秒前
牛哞完成签到,获得积分10
19秒前
德烁完成签到,获得积分10
19秒前
19秒前
小洁完成签到 ,获得积分0
19秒前
Yana完成签到,获得积分10
20秒前
zpl完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187480
求助须知:如何正确求助?哪些是违规求助? 9575554
关于积分的说明 21841909
捐赠科研通 7785230
什么是DOI,文献DOI怎么找? 3434949
关于科研通互助平台的介绍 2559412
邀请新用户注册赠送积分活动 2481898